A Long-Term Safety Extension of Studies ABE4869g and ABE4955g in Participants With Mild to Moderate Alzheimer's Disease Treated With Crenezumab
A Multicenter, Open-Label, Long-Term Safety Extension of Phase II Studies ABE4869g and ABE4955g in Patients With Mild to Moderate Alzheimer's Disease
Sponsor: Genentech, Inc.
Listed as NCT01723826, this PHASE2 trial focuses on Alzheimer's Disease and remains completed. Sponsored by Genentech, Inc., it has been updated 12 times since 2012, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
12 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Mar 2020 — Jan 2021 [monthly]
Completed PHASE2
▶ Show 7 earlier versions
-
Mar 2019 — Mar 2020 [monthly]
Completed PHASE2
-
Jun 2018 — Mar 2019 [monthly]
Completed PHASE2
-
Feb 2018 — Jun 2018 [monthly]
Completed PHASE2
-
Aug 2017 — Feb 2018 [monthly]
Completed PHASE2
-
May 2017 — Aug 2017 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Feb 2017 — May 2017 [monthly]
Active Not Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE2
First recorded
Dec 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Genentech, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Albacete, Spain , BArcelon, Spain , Barakaldo, Spain , Bath, United Kingdom , Bennington, United States , Berlin, Germany , Boca Raton, United States , Brentford, United Kingdom , Brighton, United Kingdom , Bron, France and 72 more locations